Delgocitinib Synthesis Information from Patent US8609647
Patent US8609647 provides details on the synthesis of delgocitinib [1]. The patent describes various routes and intermediates for producing this Janus kinase (JAK) inhibitor.
What are the key steps in delgocitinib synthesis?
The patent outlines specific chemical reactions and purification methods. One example within the patent illustrates a method for preparing a key intermediate, N-(cyclopentyl)-N-(1-(piperidin-4-yl)ethyl)-3-(difluoromethyl)-1H-pyrazole-5-carboxamide [1]. This involves multiple reaction steps, including the formation of amides and the use of specific reagents to achieve the desired molecular structure.
Where can I find patent information on delgocitinib synthesis?
Patent US8609647 is a primary source for synthesis information [1]. For broader patent landscape analysis and related intellectual property, DrugPatentWatch.com can be a valuable resource [2].
How does delgocitinib work?
Delgocitinib is a Janus kinase (JAK) inhibitor [3]. JAKs are enzymes involved in signaling pathways that play a role in inflammation and immune responses [3]. By inhibiting these enzymes, delgocitinib can help to reduce inflammation associated with certain conditions.
When does the patent for delgocitinib expire?
Patent expiry dates are complex and can involve multiple patents covering different aspects of a drug, including its synthesis, formulation, and use. Information on specific patent expiry timelines for delgocitinib can be found through specialized patent tracking services like DrugPatentWatch.com [2].
What are the regulatory approvals for delgocitinib?
Delgocitinib has received regulatory approval in Japan under the brand name Corectim for the treatment of atopic dermatitis [4].
What are the approved uses for delgocitinib?
Delgocitinib is approved for the treatment of atopic dermatitis [4].
What are the potential side effects of delgocitinib?
Common side effects reported for delgocitinib include nasopharyngitis, eczema, dermatitis, and influenza [4].
---
Sources:
[1] US Patent 8,609,647 B2. (2013). Janus kinase inhibitors. Google Patents. Retrieved from https://patents.google.com/patent/US8609647B2
[2] DrugPatentWatch.com. Retrieved from https://drugpatentwatch.com/
[3] Delgocitinib. (n.d.). DrugBank. Retrieved from https://go.drugbank.com/drugs/DB15661
[4] Corectim® topical cream approved in Japan for atopic dermatitis. (2020). Pharma Japan. Retrieved from https://www.pharmaceutical-technology.com/news/corectim-topical-cream-japan-atopic-dermatitis/